Here are the 10-K annual reports from Solventum Corporation (SOLV) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow SOLV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SOLV filings page.
Solventum Corporation filed its Annual Report on Form 10-K describing its global healthcare operations, spin-off risks and capital structure.
The company reports an aggregate market value of common stock held by non‑affiliates of about $13.1 billion as of its most recent second fiscal quarter and 173,493,005 shares outstanding as of February 18, 2026. Its 2025 sales were led by MedSurg at 57.9%, with Dental Solutions at 16.2% and Health Information Systems at 16.3%.
Solventum highlights its separation from 3M, noting potential challenges in systems, capital access and the loss of 3M scale benefits. As of December 31, 2025, it carried approximately $5 billion of outstanding debt. The report also notes the 2025 acquisition of Acera Surgical and the sale of its Purification and Filtration business to Thermo Fischer Scientific Inc., along with extensive regulatory, environmental, data privacy and healthcare policy risks.